JYNT trades 140.1% below Wall Street's consensus target of $20.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes JYNT achieves its forward estimates and maintains a stable P/E multiple of 30.1x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 30, 2026, The Joint Corp. (JYNT) has a Wall Street consensus price target of $20.00, based on estimates from 8 covering analysts. With the stock currently trading at $8.33, this represents a potential upside of +140.1%. The company has a market capitalization of $119M.
Analyst price targets range from a low of $20.00 to a high of $20.00, representing a 0% spread in expectations. The median target of $20.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, JYNT trades at a trailing P/E of 43.8x and forward P/E of 30.1x. Analysts expect EPS to grow +21.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $6.52, with bear and bull scenarios of $4.11 and $8.59 respectively. Model confidence stands at 41/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
XPOFXponential Fitness, Inc. | $267M | $7.15 | $7.00 | -2.1% | Buy | 15.3x | 14 |
SKINThe Beauty Health Company | $92M | $0.71 | $1.53 | +114.7% | Hold | — | 14 |
FXNCFirst National Corporation | $272M | $30.03 | $21.00 | -30.1% | Buy | 12.8x | 1 |
USPHU.S. Physical Therapy, Inc. | $1.0B | $68.82 | $96.00 | +39.5% | Buy | 23.8x | 13 |
ACHCAcadia Healthcare Company, Inc. | $2.5B | $27.69 | $28.33 | +2.3% | Buy | 18.4x | 25 |
ENSGThe Ensign Group, Inc. | $9.2B | $158.19 | $222.33 | +40.5% | Buy | 20.9x | 13 |
ADUSAddus HomeCare Corporation | $1.8B | $98.05 | $122.00 | +24.4% | Buy | 14.0x | 16 |
UNHUnitedHealth Group Incorporated | $381.1B | $419.82 | $425.81 | +1.4% | Buy | 22.8x | 52 |
CVSCVS Health Corporation | $132.2B | $103.58 | $103.64 | +0.1% | Buy | 14.0x | 41 |
CICigna Corporation | $73.5B | $278.74 | $340.91 | +22.3% | Buy | 9.2x | 39 |
Quick answers to the most common questions about buying JYNT stock.
The consensus Wall Street price target for JYNT is $20, representing 140.1% upside from the current price of $8.33. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
JYNT has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $20 implies 140.1% upside from current levels.
JYNT trades at a forward P/E of 30.1048x, representing a moderate valuation. With analysts targeting $20 (140.1% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $20 for JYNT, while the most conservative target is $20. The consensus of $20 represents the median expectation. Our quantitative valuation model projects a bull case target of $9 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
JYNT is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month JYNT stock forecast based on 8 Wall Street analysts shows a consensus price target of $20, with estimates ranging from $20 (bear case) to $20 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $7, with bear/bull scenarios of $4/$9.
Our quantitative valuation model calculates JYNT's fair value at $7 (base case), with a bear case of $4 and bull case of $9. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 41/100.
JYNT trades at a forward P/E ratio of 30.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 43.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on JYNT, with a "Buy" consensus rating and $20 price target (140.1% upside). 5 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
JYNT analyst price targets range from $20 to $20, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $20 consensus represents the middle ground. Our model's $4-$9 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.